Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study

Basit Öğe Kaydı
dc.authoridGencer, Serap/0000-0002-3217-6305
dc.authoridMeric Koc, Meliha/0000-0002-0563-6900
dc.authoridKARABAY, OGUZ/0000-0003-1514-1685
dc.authoridMUTLU YILMAZ, Esmeray/0000-0003-2569-7601
dc.authoridUysal, Serhat/0000-0002-4294-5999
dc.authoridCag, Yasemin/0000-0002-9983-0308
dc.authoridUygun Kizmaz, Yesim/0000-0002-8208-8485
dc.contributor.authorErdem, Hakan
dc.contributor.authorCag, Yasemin
dc.contributor.authorGencer, Serap
dc.contributor.authorUysal, Serhat
dc.contributor.authorKarakurt, Zuhal
dc.contributor.authorHarman, Rezan
dc.contributor.authorAslan, Emel
dc.date.accessioned2025-01-27T20:38:58Z
dc.date.available2025-01-27T20:38:58Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractVentilator-associated pneumonia (VAP) due to Acinetobacter spp. is one of the most common infections in the intensive care unit. Hence, we performed this prospective-observational multicenter study, and described the course and outcome of the disease. This study was performed in 24 centers between January 06, 2014, and December 02, 2016. The patients were evaluated at time of pneumonia diagnosis, when culture results were available, and at 72 h, at the 7th day, and finally at the 28th day of follow-up. Patients with coexistent infections were excluded and only those with a first VAP episode were enrolled. Logistic regression analysis was performed. A total of 177 patients were included; empiric antimicrobial therapy was appropriate (when the patient received at least one antibiotic that the infecting strain was ultimately shown to be susceptible) in only 69 (39%) patients. During the 28-day period, antibiotics were modified for side effects in 27 (15.2%) patients and renal dose adjustment was made in 38 (21.5%). Ultimately, 89 (50.3%) patients died. Predictors of mortality were creatinine level (OR, 1.84 (95% CI 1.279-2.657); p = 0.001), fever (OR, 0.663 (95% CI 0.454-0.967); p = 0.033), malignancy (OR, 7.095 (95% CI 2.142-23.500); p = 0.001), congestive heart failure (OR, 2.341 (95% CI 1.046-5.239); p = 0.038), appropriate empiric antimicrobial treatment (OR, 0.445 (95% CI 0.216-0.914); p = 0.027), and surgery in the last month (OR, 0.137 (95% CI 0.037-0.499); p = 0.003). Appropriate empiric antimicrobial treatment in VAP due to Acinetobacter spp. was associated with survival while renal injury and comorbid conditions increased mortality. Hence, early diagnosis and appropriate antibiotic therapy remain crucial to improve outcomes.
dc.identifier.doi10.1007/s10096-019-03691-z
dc.identifier.endpage52
dc.identifier.issn0934-9723
dc.identifier.issn1435-4373
dc.identifier.issue1
dc.identifier.pmid31502120
dc.identifier.scopus2-s2.0-85073948773
dc.identifier.scopusqualityQ1
dc.identifier.startpage45
dc.identifier.urihttps://doi.org/10.1007/s10096-019-03691-z
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23818
dc.identifier.volume39
dc.identifier.wosWOS:000511888500006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofEuropean Journal of Clinical Microbiology & Infectious Diseases
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectVentilator-associated pneumonia
dc.subjectVAP
dc.subjectPneumonia
dc.subjectAcinetobacter
dc.subjectMortality
dc.subjectTreatment
dc.titleTreatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu